4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000899243-18-015158
Chief Executive Officer sold 15,000 shares at an average $69.36 ($1,040,400)
- Chief Executive Officer gave up 741 shares (to pay taxes)
- Chief Executive Officer acquired 15,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2018-06-01 | Option exercise | +15,000 | $1.81 | $27,150 | 163,560 | D |
| Kulkarni Samarth Chief Executive Officer | 2018-06-01 | Sale | −4,600 | $67.28 | $309,488 | 158,960 | D |
| Kulkarni Samarth Chief Executive Officer | 2018-06-01 | Sale | −10,400 | $70.28 | $730,912 | 148,560 | D |
| Kulkarni Samarth Chief Executive Officer | 2018-06-04 | Shares withheld for taxes | −741 | $67.13 | $49,743 | 147,819 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2018-06-01 | Option exercise · Employee Stock Option (right to buy) | −15,000 | 264,558 | D | ||
| Open-market sales · 15,000 sh · avg $69.36 · $1,040,400 | |||||||
Loading xslF345X03/doc4.xml…